Denali Therapeutics Past Earnings Performance
Past criteria checks 0/6
Denali Therapeutics's earnings have been declining at an average annual rate of -20.9%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 7.4% per year.
Key information
-20.9%
Earnings growth rate
-11.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 7.4% |
| Return on equity | -32.4% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Jan 09We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
Dec 09
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
Aug 20Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Jul 26Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%
May 23Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
May 13An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued
Apr 17Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Mar 21Denali: Leveraging Transport Vehicle Technology For Neurological Gains
Mar 07Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Feb 21Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet
Jan 26We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Nov 20Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking
Oct 09Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Aug 22Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price
May 02Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be
Mar 04Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation
Feb 06These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat
Nov 09Denali Therapeutics proposes $250M stock offering; shares down 6% post market
Oct 18Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Oct 12Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122
Oct 10Revenue & Expenses Breakdown
How Denali Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -427 | 100 | 0 |
| 30 Jun 24 | 1 | -420 | 101 | -27 |
| 31 Mar 24 | 295 | -137 | 101 | 0 |
| 31 Dec 23 | 331 | -145 | 103 | 0 |
| 30 Sep 23 | 341 | -124 | 102 | 0 |
| 30 Jun 23 | 343 | -128 | 100 | 194 |
| 31 Mar 23 | 101 | -371 | 95 | 0 |
| 31 Dec 22 | 108 | -326 | 90 | 0 |
| 30 Sep 22 | 111 | -303 | 89 | 0 |
| 30 Jun 22 | 112 | -284 | 85 | 0 |
| 31 Mar 22 | 83 | -286 | 83 | 0 |
| 31 Dec 21 | 49 | -291 | 79 | 0 |
| 30 Sep 21 | 353 | 30 | 75 | 0 |
| 30 Jun 21 | 357 | 56 | 72 | 0 |
| 31 Mar 21 | 340 | 58 | 67 | 0 |
| 31 Dec 20 | 336 | 71 | 60 | 0 |
| 30 Sep 20 | 24 | -228 | 53 | 0 |
| 30 Jun 20 | 28 | -216 | 49 | 0 |
| 31 Mar 20 | 26 | -215 | 50 | 0 |
| 31 Dec 19 | 27 | -198 | 46 | 0 |
| 30 Sep 19 | 148 | -66 | 47 | 0 |
| 30 Jun 19 | 135 | -55 | 44 | 0 |
| 31 Mar 19 | 133 | -52 | 36 | 0 |
| 31 Dec 18 | 129 | -36 | 32 | 0 |
| 30 Sep 18 | 3 | -137 | 26 | 0 |
| 30 Jun 18 | 2 | -123 | 21 | 0 |
| 31 Mar 18 | 1 | -91 | 18 | 0 |
| 31 Dec 17 | 0 | -88 | 16 | 0 |
| 30 Sep 17 | 0 | -85 | 14 | 17 |
| 30 Jun 17 | 0 | -93 | 13 | 39 |
| 31 Mar 17 | 0 | -90 | 12 | 55 |
| 31 Dec 16 | 0 | -87 | 12 | 0 |
Quality Earnings: DNLI is currently unprofitable.
Growing Profit Margin: DNLI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DNLI is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.
Accelerating Growth: Unable to compare DNLI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DNLI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: DNLI has a negative Return on Equity (-32.42%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 01:36 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Denali Therapeutics Inc. is covered by 23 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Caroline Palomeque | Berenberg |
| Tazeen Ahmad | BofA Global Research |